In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bio Products' Coagadex Gets CHMP OK After Fast Track Assessment

This article was originally published in Scrip

Executive Summary

Coagadex, Bio Products Laboratory Limited's purified coagulation Factor X concentrate derived from human plasma, got the greenlight Jan. 29 from the EU's top scientific advisory panel, the Committee for Medicinal Products for Human Use (CHMP), as the first replacement therapy for patients with hereditary Factor X deficiency, a rare inherited bleeding disorder, just over three months after the therapy won marketing approval in the US.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts